

Highlights of This Issue 4417

SPECIAL FEATURES

CCR Translations

- 4419** *TP53* Mutations and Lung Cancer: Not All Mutations Are Created Equal
Ramaswamy Govindan and Jason Weber
See related article, p. 4647
- 4422** “Companion Diagnostics”: Has Their Time Come and Gone?
Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst
See related article, p. 4488

CCR New Strategies

- 4425** New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Juliane M. Jürgensmeier, Joseph P. Eder, and Roy S. Herbst

CCR Perspectives in Drug Approval

- 4436** FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Laleh Amiri-Kordestani, Gideon M. Blumenthal, Qiang Casey Xu, Lijun Zhang, Shenghui W. Tang, Linan Ha, Wendy C. Weinberg, Bo Chi, Reyes Candau-Chacon, Patricia Hughes, Anne M. Russell, Sarah Pope Miksinski, Xiao Hong Chen, W. David McGuinn, Todd Palmby, Sarah J. Schrieber, Qi Liu, Jian Wang, Pengfei Song, Nitin Mehrotra, Lisa Skarupa, Kathleen Clouse, Ali Al-Hakim, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur, and Patricia Cortazar

Molecular Pathways

- 4442** Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

CANCER THERAPY: CLINICAL

- 4449** Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, H.-Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna Pavlick, Melvin T. Chin, Steven J. O’Day, Samuel C. Blackman, C. Martin Curtis, Peter Lebowitz, Bo Ma, Daniele Ouellet, and Richard F. Kefford
- 4459** p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8⁺ T-cell Responses
Nicola R. Hardwick, Mary Carroll, Teodora Kaltcheva, Dajun Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakhri, Yun Yen, Jonathan Espenschied, Joshua D.I. Ellenhorn, Don J. Diamond, and Vincent Chung
- 4471** Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Jacques Medioni, Gael Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyon, Gerard Maruani, Pascal Houillier, Sarah Mackenzie, Stephanie Renaux, Jean-Francois Dufour-Lamartinié, Reza Elaidi, Celine Lerest, and Stephane Oudard

PERSONALIZED MEDICINE AND IMAGING

- 4478** Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer
Christiane Amendt, Eike Staub, Manja Friese-Hamim, Stephan Störkel, and Christopher Stroh
- 4488** Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
Hartmut Koeppen, Wei Yu, Jiping Zha, Ajay Pandita, Elicia Penuel, Linda Rangell, Rajiv Raja, Sankar Mohan, Rajesh Patel, Rupal Desai, Ling Fu, An Do, Vaishali Parab, Xiaoling Xia, Tom Januario, Sharianna G. Louie, Ellen Filvaroff, David S. Shames, Ignacio Wistuba, Marina Lipkind, Jenny Huang, Mirella Lazarov, Vanitha Ramakrishnan, Lukas Amler, See-Chun Phan, Premal Patel, Amy Peterson, and Robert L. Yauch
See related commentary, p. 4422

Table of Contents

- 4499** **A *let-7* microRNA-Binding Site Polymorphism in *KRAS* Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy**
Zenia Saridaki, Joanne B. Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, and Sabine Tejpar

- 4511** ***FcγRIIIa* and *FcγRIIIa* Polymorphisms and Cetuximab Benefit in the Microscopic Disease**
Francesco Sclafani, David Gonzalez de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaume Capdevila, Bengt Glimelius, Susana Roselló Keränen, Andrew Wotherspoon, Gina Brown, Diana Tait, Ruwaida Begum, Janet Thomas, Jacqueline Oates, and Ian Chau

- 4520** **Cell and Molecular Determinants of *In Vivo* Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts**
Santi Suryani, Hernan Carol, Triona Ni Chonghaile, Viktoras Fris mantas, Chintanu Sarmah, Laura High, Beat Bornhauser, Mark J. Cowley, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Elise Tonna, Luke Jones, Donya Moradi Manesh, Raushan T. Kurmasheva, Catherine Billups, Warren Kaplan, Anthony Letai, Jean-Pierre Bourquin, Peter J. Houghton, Malcolm A. Smith, and Richard B. Lock

- 4532** **Noninvasive Detection of Glutamate Predicts Survival in Pediatric Medulloblastoma**
Martin Wilson, Simrandip K. Gill, Lesley MacPherson, Martin English, Theodoros N. Arvanitis, and Andrew C. Peet

- 4540** **Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of *IGH***
David Wu, Ryan O. Emerson, Anna Sherwood, Mignon L. Loh, Anne Angiolillo, Bryan Howie, Jennifer Vogt, Mark Rieder, Ilan Kirsch, Christopher Carlson, David Williamson, Brent L. Wood, and Harlan Robins

- 4549** **The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer**
Alison Backen, Andrew G. Renehan, Andrew R. Clamp, Carlo Berzuini, Cong Zhou, Amit Oza, Selina Bannoo, Stefan J. Scherer, Rosamonde E. Banks, Caroline Dive, and Gordon C. Jayson

CANCER THERAPY: PRECLINICAL

- 4559** **Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer**
Zhe Zhang, Jiping Wang, Dongmei Ji, Chenchen Wang, Rujiao Liu, Zheng Wu, Lian Liu, Dan Zhu, Jinjia Chang, Ruixuan Geng, Lei Xiong, Qiangyi Fang, and Jin Li

- 4574** **SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38⁺ Hematologic Malignancies**
Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skaletskaya, Victor S. Goldmacher, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, and Véronique Blanc

- 4584** **Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth**
Savita Sankar, Emily R. Theisen, Jared Bearss, Timothy Mulvihill, Laura M. Hoffman, Venkataswamy Sorna, Mary C. Beckerle, Sunil Sharma, and Stephen L. Lessnick


BIOLOGY OF HUMAN TUMORS

- 4598** **Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis**
Zhaojun Liu, Jun Zhang, Yanhong Gao, Lirong Pei, Jing Zhou, Liankun Gu, Lianhai Zhang, Budong Zhu, Naoko Hattori, Jiafu Ji, Yasuhito Yuasa, Woocho Kim, Toshikazu Ushijima, Huidong Shi, and Dajun Deng

- 4613** **Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002**
Sébastien Couraud, Felipe Vaca-Paniagua, Stéphanie Villar, Javier Oliver, Tibor Schuster, Hélène Blanché, Nicolas Girard, Jean Trédaniel, Laurent Guilleminault, Radj Gervais, Nathalie Prim, Michel Vincent, Jacques Margery, Sébastien Larivé, Pascal Foucher, Bernard Duvert, Maxime Vallee, Florence Le Calvez-Kelm, James McKay, Pascale Missy, Franck Morin, Gérard Zalzman, Magali Olivier, and Pierre-Jean Souquet for the BioCAST/IFCT-1002 investigators



Table of Contents

- 4625** Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer
Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kenichi Takayama, Toru Sugihara, Daisuke Obinata, Yuta Yamada, Jimpei Kumagai, Haruki Kume, Yasuyoshi Ouchi, Satoshi Inoue, and Yukio Homma
- 4636** miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Sajni Josson, Murali Gururajan, Peizhen Hu, Chen Shao, Gina Chia-Yi Chu, Haiyen E. Zhau, Chunyan Liu, Kaiqin Lao, Chia-Lun Lu, Yi-Tsung Lu, Jake Lichterman, Srinivas Nandana, Quanlin Li, Andre Rogatko, Dror Berel, Edwin M. Posadas, Ladan Fazli, Dhruv Sareen, and Leland W.K. Chung
- 4647** Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer
Miguel A. Molina-Vila, Jordi Bertran-Alamillo, Amaya Gascó, Clara Mayo-de-las-Casas, María Sánchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo G. Favaretto, Andrés F. Cardona, Alain Vergnenègre, Margarita Majem, Bartomeu Massuti, Teresa Morán, Enric Carcereny, Santiago Viteri, and Rafael Rosell
See related commentary, p. 4419
- 4660** An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non-Small Cell Lung Cancer
Satoshi Noguchi, Akira Saito, Masafumi Horie, Yu Mikami, Hiroshi I. Suzuki, Yasuyuki Morishita, Mitsuhiro Ohshima, Yoshimitsu Abiko, Johanna Sofia Margareta Mattsson, Helena König, Miriam Lohr, Karolina Edlund, Johan Botling, Patrick Micke, and Takahide Nagase
- 4673** To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN
Daniel J. Shiwerski, Chunbo Shao, Anke Bill, Jean Kim, Dong Xiao, Carol A. Bertrand, Raja S. Seethala, Daisuke Sano, Jeffery N. Myers, Patrick Ha, Jennifer Grandis, L. Alex Gaither, Manojkumar A. Puthenveedu, and Umamaheswar Duvvuri
- 4689** TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome 
Tiantian Sun, Wan Du, Hua Xiong, Yanan Yu, Yurong Weng, Linlin Ren, Huijun Zhao, Yingchao Wang, Yingxuan Chen, Jie Xu, Yongbing Xiang, Wenxin Qin, Weibiao Cao, Weiping Zou, Haoyan Chen, Jie Hong, and Jing-Yuan Fang
- 4705** Decreased Expression of miR216a Contributes to Non-Small-Cell Lung Cancer Progression
Ren-Tao Wang, Meng Xu, Cheng-Xiong Xu, Zhi-Gang Song, and Hua Jin
- 4717** GSK-3 β -Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion
Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xing-Zheng Zheng, Yong-Xin Zou, Xin Li, Lin Hou, Michael A. McNutt, and Bo Zhang

 AC icon indicates Author Choice


 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.



Clinical Cancer Research

20 (17)

Clin Cancer Res 2014;20:4417-4729.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/20/17>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/17>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.